MetLife Investment Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $586K | Sell |
23,108
-1,983
| -8% | -$46.9K | ﹤0.01% | 1827 |
|
|
2026
Q1 | $567K | Sell |
25,091
-320
| -1% | -$7.11K | ﹤0.01% | 1689 |
|
|
2025
Q4 | $658K | Sell |
25,411
-2,136
| -8% | -$50.8K | ﹤0.01% | 1664 |
|
|
2025
Q3 | $710K | Hold |
27,547
| – | – | ﹤0.01% | 1644 |
|
|
2025
Q2 | $658K | Hold |
27,547
| – | – | ﹤0.01% | 1545 |
|
|
2025
Q1 | $685K | Sell |
27,547
-336
| -1% | -$8.04K | ﹤0.01% | 1549 |
|
|
2024
Q4 | $525K | Buy |
27,883
+1,471
| +6% | +$25.8K | ﹤0.01% | 1771 |
|
|
2024
Q3 | $398K | Hold |
26,412
| – | – | ﹤0.01% | 1904 |
|
|
2024
Q2 | $756K | Buy |
26,412
+2,422
| +10% | +$68.9K | ﹤0.01% | 1504 |
|
|
2024
Q1 | $701K | Hold |
23,990
| – | – | ﹤0.01% | 1501 |
|
|
2023
Q4 | $809K | Hold |
23,990
| – | – | 0.01% | 1422 |
|
|
2023
Q3 | $736K | Hold |
23,990
| – | – | 0.01% | 1398 |
|
|
2023
Q2 | $961K | Buy |
23,990
+319
| +1% | +$13.2K | 0.01% | 1289 |
|
|
2023
Q1 | $966K | Hold |
23,671
| – | – | 0.01% | 1235 |
|
|
2022
Q4 | $914K | Hold |
23,671
| – | – | 0.01% | 1265 |
|
|
2022
Q3 | $1.26M | Hold |
23,671
| – | – | 0.01% | 1080 |
|
|
2022
Q2 | $1.38M | Hold |
23,671
| – | – | 0.01% | 1055 |
|
|
2022
Q1 | $1.81M | Buy |
23,671
+8,425
| +55% | +$562K | 0.01% | 1040 |
|
|
2021
Q4 | $917K | Hold |
15,246
| – | – | 0.01% | 1165 |
|
|
2021
Q3 | $854K | Sell |
15,246
-1,510
| -9% | -$87K | 0.01% | 1207 |
|
|
2021
Q2 | $1.02M | Hold |
16,756
| – | – | 0.01% | 1151 |
|
|
2021
Q1 | $1.17M | Sell |
16,756
-1,751
| -9% | -$125K | 0.01% | 1084 |
|
|
2020
Q4 | $1.11M | Hold |
18,507
| – | – | 0.01% | 1083 |
|
|
2020
Q3 | $1.11M | Hold |
18,507
| – | – | 0.01% | 976 |
|
|
2020
Q2 | $971K | Hold |
18,507
| – | – | 0.01% | 1051 |
|
|
2020
Q1 | $621K | Hold |
18,507
| – | – | 0.01% | 1103 |
|
|
2019
Q4 | $838K | Hold |
18,507
| – | – | 0.01% | 1183 |
|
|
2019
Q3 | $705K | Hold |
18,507
| – | – | 0.01% | 1238 |
|
|
2019
Q2 | $805K | Sell |
18,507
-37,014
| -67% | -$1.57M | 0.01% | 1218 |
|
|
2019
Q1 | $2.11M | Buy |
55,521
+37,014
| +200% | +$1.44M | 0.01% | 1219 |
|
|
2018
Q4 | $796K | Hold |
18,507
| – | – | 0.01% | 1117 |
|
|
2018
Q3 | $910K | Hold |
18,507
| – | – | 0.01% | 1176 |
|
|
2018
Q2 | $593K | Hold |
18,507
| – | – | 0.01% | 1306 |
|
|
2018
Q1 | $576K | Hold |
18,507
| – | – | 0.01% | 1290 |
|
|
2017
Q4 | $845K | Buy |
+18,507
| New | +$733K | 0.01% | 1103 |
|
Other funds holding PCRX
DPCM
MetLife Investment Management's PCRX Position: Q2 2026 in Review
MetLife Investment Management reduced its Pacira BioSciences (PCRX) stake by 7.9% in Q2 2026, selling an estimated $46.9K and leaving 23,108 shares worth $586K. The position accounts for ﹤0.01% of the portfolio, ranked #1827.
MetLife Investment Management first reported a position in PCRX in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.11M in Q1 2019. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- MetLife Investment Management held 23,108 shares of Pacira BioSciences worth $586K as of Q2 2026.
- MetLife Investment Management sold 1,983 Pacira BioSciences shares in Q2 2026, an estimated $46.9K.
- Pacira BioSciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1827 holding.
- MetLife Investment Management first reported a position in Pacira BioSciences in Q4 2017 and has held it in 35 quarters since.
- MetLife Investment Management's Pacira BioSciences position peaked at $2.11M in Q1 2019.
- 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.